Benchmark N-glycoproteomics study of common differential tissue and serum N-glycoproteins of patients with hepatocellular carcinoma.

For hepatocellular carcinoma (HCC), N- glycosylation has been proved to be widely involved in various aspects of the disease, including development, metastasis, subtyping, diagnosis and prognosis. The common practice is to discover biomarkers in situ of cancer occurrence (i.e., cancer vs. adjacent tissues) yet to clinically monitor in sera because of non-invasiveness. This study benchmarks N- glycoproteomics characterization of common differential tissue and serum N- glycoproteins of patients with HCC. Differential N- glycosylation in matched tissue and serum samples from the same patients were quantitatively characterized at the intact N- glycopeptide molecular level, and 29 common N- glycoproteins were found. Subcellular localization analysis was carried out to confirm the tissue originality. Secreted N- glycoprotein APOH was up-regulated, and transmembrane and intracellular N- glycoproteins including OSMR, GAT2, CSF-1 and MAGI3 were down-regulated. [Display omitted] • Comparative N-glycoproteomics study of matched tissue and serum from HCC patients. • 344 and 127 differentially expressed N-glycoproteins were quantified at the intact N-glycopeptide level from the tissue and serum samples, and 29 are common. • Subcellular localization confirmed the tissue origin of the 29 common N-glycoproteins. [ABSTRACT FROM AUTHOR]